spacer
home > epc > Summer 2013
PUBLICATIONS

European Pharmaceutical Contractor

epc
Summer 2013

   
Text
PDF
bullet
introduction

Editor’s Letter

Editor's letter

Graham Hughes gives readers a brief outline of his pick of this issue’s articles.

 
view
download pdf
bullet
Marketplace & Business: Translation Feature
Big Pharma 2.0

What Does the Future Hold?

Hellmuth Broda at Infosys explores some of the achievements that the pharmaceutical industry has gained over the past few decades, as well as giving some predictions for what we could expect to see as the 21st century unfolds.
 
view
download pdf
bullet
Clinical Trials
Quality Analysis

What Price Quality?

Robert J Hayes at Cold Chain Consultants (UK) Ltd outlines some of the key factors that must be considered in order to understand why failure occurs in clinical trials, including the ability to understand the Cost of Quality, as well as how to avoid poor quality.
 
view
download pdf

Clinical Trials

Virtual Trial Methods

The increase in drug development costs, in addition to the over-saturation of the market, has meant that companies must expand their outreach, while contracting their costs. Kai Langel at eClinicalHealth Ltd believes that this may be possible through virtual trials.

 
view
download pdf
bullet
Legal & Regulatory
Non-Animal Toxicology Testing

Alternative Action

Animal testing methods in drug development and testing are increasingly becoming less and less accepted in today’s society. Jarrod Bailey at the New England Anti-Vivisection Society discusses some of the possible alternatives.
 
view
download pdf
bullet
Clinical Research

In Conclusion

Ignorance is Far From Bliss

Vaccinations are essential for society, otherwise we risk epidemics of once-common diseases that have been virtually eliminated, argues Graham Hughes.

 
view
download pdf
bullet
Science & Innovation
Animal Testing Alternatives

A Driving Force

Using examples from the pharmaceutical and cosmetics industries, Andre Menache at Antidote Europe develops the argument for non-animal toxicology testing, providing evidence as to why other options are increasingly being considered.

 
view
download pdf
Toxicology

New Rules for New Tests

The world of toxicology is facing enormous changes. Daryl S Paulson at BioScience Laboratories, Inc delves into the world of animal testing, and presents some non-animal methods.
 
view
download pdf
bullet
DATA MANAGEMENT
Data Analytics

A Change in Time

Scott Setrakian at Applied Predictive Technologies explores the changes in which data is stored, analysed and managed, including ensuring that the results are more precise and less open to common errors.
 
view
download pdf
bullet
Risk Management
Facility Protection

Risky Business

Mark Lamond at FM Global realises that the process of managing risk is more of an issue today than it has ever been, and to combat this growing demand, companies must address some of the challenges associated with effective risk-management.
 
view
download pdf
Risk-Based Monitoring

An Important Decision

Recent guidance has outlined the need for quality risk management to aid pharma companies in their quest for discovery. However, as Marta Gibala and Michael Sigmund of SSS International Clinical Research point out, many are reluctant to commit to it.
 
view
download pdf
bullet
Review
Event Review

Euro Exchange

Graham Hughes reviews the DIA Euromeeting, which took place in Amsterdam in March this year.
 
view
download pdf
bullet
Regional Focus
Regional Focus

Good Strategy

In the second of a two-part article, industry reporter Nick Charles returns to the East to continue his analysis of China’s life sciences industry. In this final installment, he focuses on the importance of timing, investment and partnerships.
 
view
download pdf
Clinical Trials: Serbia

A Region Reborn

Jelena Barjaktarovic, Maxim Belotserkovsky, Mirjana Jovanovic and Melita Zonic at PSI CRO AG explain why the future of clinical trials may shift to a Balkan state, as well as weighing up some potential problems that must be overcome.

 
view
download pdf

Research and Development
Stimulating Innovation in R&D

Better Together

It is necessary for pharma companies to constantly evolve in order for them to remain relevant and in demand. Gilles Toulemonde at Inova Software outlines some possible ways in which this innovation can be maintained.
 
view
download pdf
Metabolomics

Mapping the Maze

As metabolomics emerges as a leading technology, Nicolas Schauer and Dierk-Christoph Pöther at Metabolomic Discoveries explain some of the key benefits that this novel tool may present to biochemical mechanisms, diseases and nutrition.
 
view
download pdf

Interview
Interview: David Underwood

Hitting New Targets

Founding CEO and Chairman of Quanticate speaks to EPC about some of the daily challenges that he faces, as well as the possible future direction of the industry.
 
view
download pdf

Interview: Heather Fraser

Life Lessons

EPC talks to IBM about the clinical trials sector, particularly on what companies must do in order to keep running smoothly.

 
view
download pdf
   
spacer



Published quarterly in
February, May,
August, and November

News and Press Releases

Pharmaceutical Packaging and Labelling Summit in Zurich; ACG presentation

At next week’s Pharmaceutical Packaging and Labelling Summit in Zurich (18-19 June), Dr. Eugen Hertel from ACG will be speaking on: Challenges for Global Pharma companies to Implement Anti-Counterfeit Strategy for Russian Track & Trace Regulation. This presentation will include details around ‘the fight against counterfeit medicine - there have been and still are worldwide initiatives to make the supply chain and the safety of medicines secure. After large markets such as the USA and Europe passed their laws and regulations for the pharmaceutical manufacturing companies and established the IT infrastructure, Russia is now next on the move.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement